Gene · 25913
NIH grants1,830
NIH grants whose papers are about the gene, through NIH's grant-paper links.
401 to 420 of 1,830
Download this page as JSON| Grant | Title | POT1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA233490 | Genetic and Epigenetic Biomarkers for B-cell Lymphoma | 1 | 2023 |
| R01CA233512 | Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands | 1 | 2023 |
| R01CA233594 | DNA-PKcs and PIDD interaction in DNA damage response | 1 | 2023 |
| R01CA233790 | Therapeutic implication of CD38 in CLL | 1 | 2023 |
| R01CA233945 | Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL | 1 | 2023 |
| R01CA235026 | Integration of germline and tumor genomes in CLL | 1 | 2023 |
| R01CA236273 | Role of the lncRNA BORG in Breast Cancer Metastatic Progression and Recurrence | 1 | 2023 |
| R01CA236361 | Non-canonical Wnt-Receptor Signaling and Targeted Therapies | 1 | 2023 |
| R01CA240434 | Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma | 1 | 2023 |
| R01DK122734 | Quantitative magnetization transfer MRI for evaluation of renal fibrosis | 1 | 2023 |
| R01EY031939 | Targeting the Ref-1 signaling node for treating ocular neovascularization | 1 | 2023 |
| R01GM114141 | Mechanisms mediating immune response upon sensing of nuclear viral DNA | 1 | 2023 |
| R01GM130715 | PheWAS and GWAS of Telomere Length to Understand Human Disease | 1 | 2023 |
| R01GM130745 | A Bayesian nonparametric approach to superresolved tracking of multiple molecules inside living cells | 1 | 2023 |
| R01GM134005 | Novel statistical methods and tools to integrate multiple endophenotypes and functional annotation data to study the roles of rare variants in complex human diseases using sequencing data | 1 | 2023 |
| R01HL147059 | Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis | 1 | 2023 |
| R01HL148338 | Reversal of Heart Failure: Role of Vascular Recovery | 1 | 2023 |
| R03AG071549 | Telomere length analysis in the CALERIE trial | 1 | 2023 |
| R15AG069544 | Mitochondrial Dysfunction in Aging CD4 T cells in HIV-immune Non-responders. | 1 | 2023 |
| R21CA267527 | Defining the impact of mutational drivers on the immune microenvironment of CLL | 1 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25913/grants?page=21